SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K, dated August 14, 2006, reports a material event regarding the financial reporting of India Globalization Capital, Inc. (referred to in metadata as IGC Pharma, Inc.). The filing addresses the need to restate audited financial statements for the period from inception (April 29, 2005) through March 8, 2006, and for the fiscal year ended March 31, 2006.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that previously reported cash flows and the company's current cash position are not expected to be impacted by the restatement. However, the restatement will increase previously reported operating losses and net losses.
Material Changes Versus Prior Period
- Restatement Trigger: The company must record stock compensation expense for the fair value of common stock issued to founders and advisors in February 2006, which was not previously recorded.
- Impact on Losses: The restatement will result in higher operating losses and net losses for the interim and fiscal periods covered.
- Impact on Cash: No impact is expected on previously reported cash flows or the current cash position.
Guidance, Outlook, and Risks
Management Commentary and Auditor Action: The company's independent registered public accounting firm, Goldstein Golub Kessler LLP (GGK), has withdrawn its audit opinion on the financial statements for the periods from April 29, 2005, through March 31, 2006. The withdrawal letter was delivered on August 18, 2006. The company and GGK are continuing to work together to complete the audit of the restated periods.
Risks and Contingencies: The primary risk identified is the non-reliance on previously issued financial statements. The company intends to file amendments to its Form 8-K (filed March 17, 2006) and its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2006, to include the restated financial statements and amended disclosures.
Investor Verification Checklist
- Verify the specific dollar amount of the stock compensation expense to be recorded for shares issued in February 2006.
- Confirm the revised operating loss and net loss figures once the restatement is finalized.
- Review the amended Form 8-K and Form 10-KSB filings for updated disclosures.
- Monitor the status of the audit completion with Goldstein Golub Kessler LLP.